Clinical Trial Update: Evaluating the Prognostic Impact of Anti-β1AR Antibodies and Anti-L-CaC Antibodies in Patients With Dilated Cardiomyopathy

View source ↗

Summary

This clinical trial update indicates ongoing recruitment to evaluate the prognostic impact of anti-β1AR antibodies and anti-L-CaC antibodies in patients with Di…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dilated Cardiomyopathy

Drugs mentioned

• anti-L-CaC antibodies (L-type calcium channel antibodies)
• anti-β1AR antibodies (β1-adrenergic receptor antibodies)

Snippet

Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Conditions: Dilated Cardiomyopathy (DCM) | Status: RECRUITING